TEAD (ETF) participates in tumor progression, including tumor development, drug resistance, epithelial–mesenchymal transition (EMT), and metastasis, by engaging various oncogenic signaling pathways such as Wnt, TGFβ, and Hippo signaling [43]. Here, TEAD2 is linked to neoplasm.